Thompson Siegel & Walmsley LLC lessened its holdings in shares of OraSure Technologies (NASDAQ:OSUR) by 5.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 288,998 shares of the medical instruments supplier’s stock after selling 17,863 shares during the quarter. Thompson Siegel & Walmsley LLC owned 0.47% of OraSure Technologies worth $4,881,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. SG Americas Securities LLC acquired a new stake in OraSure Technologies during the 1st quarter valued at approximately $113,000. Elkfork Partners LLC bought a new position in OraSure Technologies during the 4th quarter worth approximately $143,000. Shikiar Asset Management Inc. bought a new position in OraSure Technologies during the 4th quarter worth approximately $207,000. AMP Capital Investors Ltd bought a new position in OraSure Technologies during the 4th quarter worth approximately $294,000. Finally, Quadrant Private Wealth Management LLC bought a new position in OraSure Technologies during the 4th quarter worth approximately $300,000. Hedge funds and other institutional investors own 92.13% of the company’s stock.
A number of research analysts have commented on OSUR shares. BidaskClub raised OraSure Technologies from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 15th. Zacks Investment Research downgraded OraSure Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, April 18th. ValuEngine raised OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Finally, TheStreet downgraded OraSure Technologies from a “b” rating to a “c+” rating in a report on Wednesday, May 2nd. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $20.75.
OraSure Technologies opened at $16.27 on Friday, Marketbeat.com reports. OraSure Technologies has a 52 week low of $12.86 and a 52 week high of $23.01. The company has a market cap of $997.17 million, a price-to-earnings ratio of 31.90, a PEG ratio of 4.28 and a beta of 1.69.
OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, May 2nd. The medical instruments supplier reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. The company had revenue of $41.99 million for the quarter, compared to the consensus estimate of $40.53 million. OraSure Technologies had a return on equity of 6.58% and a net margin of 9.28%. OraSure Technologies’s quarterly revenue was up 29.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.21 EPS. sell-side analysts expect that OraSure Technologies will post 0.31 earnings per share for the current year.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.